Our IP specialists work at all stage of the IP life cycle and provide strategic advice about patent, trade mark and registered designs, as well as any IP-related disputes and legal and commercial requirements.
Richard is our Managing Partner and is responsible for leading the Management Board to devise and deliver the firm's strategy.
Richard has extensive experience in the biotechnology and pharmaceutical sectors. He works closely with clients to establish a compelling commercial IP position. Richard and his team help clients to generate active and valuable patent portfolios, defending key patents on a global basis, conducting freedom to operate analyses and taking effective action against competitors.
Areas of Expertise
- Oligonucleotide technology, including aptamers, antisense and RNA interference. Richard succeeded in obtaining grant of the very first aptamer (SELEX) technology patents in Europe, and has unrivalled experience in this field.
- Adoptive T cell therapies, including CAR-T and VSTs.
- Oncolytic viruses
Richard’s clients include biotechnology companies in Europe, the US and Singapore. Richard works closely with many clients based in Singapore and is a regular visitor.
Richard has an MA in biochemistry from the University of Cambridge and is a Chartered Biologist. He joined Mewburn Ellis in 2003, qualifying as a Chartered Patent Attorney and European Patent Attorney in 2006, and was awarded a Higher Courts Litigation Certificate in 2015. He joined the partnership in 2006.
“Thorough, well-prepared and responsive.”- The Legal 500, 2017
'Key Lawyer' - The Legal 500, 2019
Client feedback: “You have provided good counsel to me and to Clovis for many years. I greatly appreciate your commitment and abilities. Your temperament and willingness to listen, assimilate and execute a strategy with such grace is remarkable. Thank you for your extraordinary efforts on behalf of Clovis”. Vanessa Appleby – Clovis Oncology